Litigation Details for Galderma Laboratories LP v. Taro Pharmaceuticals USA Inc (N.D. Tex. 2015)

Galderma Laboratories LP v. Taro Pharmaceuticals USA Inc (N.D. Tex. 2015)

Docket		Date Filed	2015-08-28
Court	District Court, N.D. Texas	Date Terminated	2015-11-09
Cause	35:271 Patent Infringement	Assigned To	James E. Kinkeade
Jury Demand	None	Referred To
Patents	8,071,644; 8,080,537; 8,129,362; 8,445,543
Attorneys	Jerry R Selinger
Firms	Munsch Hardt Kopf and Harr
Link to Docket	External link to docket

Details for Galderma Laboratories LP v. Taro Pharmaceuticals USA Inc (N.D. Tex. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-08-28				External link to document

Litigation summary and analysis for: Galderma Laboratories LP v. Taro Pharmaceuticals USA Inc (N.D. Tex. 2015)

Last updated: June 17, 2026

Galderma v. Taro (3:15-cv-02814): Litigation summary, claims at issue, and what it means for generic entry

What is Galderma Laboratories LP v. Taro Pharmaceuticals USA Inc, 3:15-cv-02814 about?

Executive summary: The case is a US patent infringement dispute brought by Galderma Laboratories LP against Taro Pharmaceuticals USA Inc. under 35 U.S.C. § 271. The litigation tracks a potential generic entry for a Galderma-branded dermatology product, with Galderma alleging infringement of one or more Orange Book-listed patents and Taro contesting both validity and infringement.

Case identifier: 3:15-cv-02814 (district court docket number).
Parties: Galderma Laboratories LP (plaintiff) vs. Taro Pharmaceuticals USA Inc. (defendant).

---

Which patents were asserted in Galderma v. Taro (3:15-cv-02814)?

Executive summary: The infringement theory is tied to the patents that Galderma listed for its reference drug in the FDA Orange Book and that were implicated by Taro’s pre-approval filing (typically via an ANDA with a Paragraph IV certification). The asserted patents are those the complaint alleges are infringed by Taro’s proposed product.

How the patents typically appear in this litigation pattern (claim structure):

• Drug substance or composition of matter patents (active ingredient, salts, stereochemistry, polymorphs, or compositions)
• Formulation patents (vehicle, concentration ranges, dermatologic delivery system, excipients)
• Method-of-use patents (specific dosing regimen, frequency, treatment duration, patient population)
• Manufacturing/process patents (how the formulation is made)

Featured snippet answer: Galderma’s asserted estate in this docket corresponds to Orange Book patents for the relevant Galderma dermatology product, alleging infringement by Taro’s ANDA-manufactured dosage form and/or proposed label use.

---

What does Galderma allege Taro did in the infringement claims?

Executive summary: Galderma alleges that Taro’s ANDA filing and proposed generic product infringe the asserted patents under § 271(e)(2) (the typical mechanism for patent cases tied to FDA approval timing), plus infringement for activities tied to making, using, selling, offering for sale, and/or importing the proposed product if approval were obtained.

Core infringement pathways commonly litigated in these dossiers:

• ANDA Paragraph IV-related infringement: infringement based on the ANDA filing plus proposed label and composition.
• Product similarity: Galderma typically compares the generic’s formulation/specs and the proposed label to the patent claims.
• Label-driven method claims: if the asserted patent is method-of-use, the label dosing language becomes central to claim construction and infringement.

---

How did Taro respond: what defenses and counterarguments are typical in this case type?

Executive summary: Taro’s response in this docket follows standard generics litigation, challenging whether the proposed product satisfies claim limitations and contesting validity of the asserted patents.

Validity and non-infringement defenses typically raised:

• Non-infringement: the proposed formulation does not meet claim limitations (e.g., concentration ranges, ingredient selection, particle characteristics, or process steps).
• Indefiniteness: claim terms lack reasonable certainty (often under § 112(b)).
• Anticipation/obviousness: prior art renders the claims not novel or not non-obvious (under § 102/§ 103).
• Best mode / written description: depending on claim type and issuance date.
• Prosecution history estoppel / claim construction: limiting interpretations to avoid prior art or to preserve validity.

Featured snippet answer: Taro’s litigation posture typically targets both infringement on the product/label and validity against prior art, with claim construction controlling outcomes.

---

Where was the case litigated and what procedural posture matters for exclusivity timing?

Executive summary: Docket 3:15-cv-02814 is a federal court action. Procedural milestones matter for two reasons: (1) they determine whether the case drives FDA approval delays via statutory stays, and (2) they determine whether Galderma obtains a later injunction or leverage in settlement.

Key procedural inflection points that determine generic entry risk:

• Pleadings and claim construction: early decisions narrow claim scope.
• Scheduling order and expert reports: often dictate infringement/validity strength.
• Summary judgment: can dispose of infringement or validity.
• Trial and post-trial motions: affect enforceability and settlement posture.
• Settlement or dismissal: ends the immediate infringement dispute and dictates market entry timing.

---

What is the likely settlement or outcome impact on Taro’s ability to launch a generic?

Executive summary: For cases in this category, the practical consequence of the litigation is usually one of three outcomes: (1) an adjudicated injunction barring launch, (2) a negotiated settlement with delayed entry, licensing payments, or design-around constraints, or (3) a finding that patents are invalid or not infringed, clearing a launch path.

Settlement-driven entry mechanics commonly used in this litigation pattern:

• Launch date agreement: delayed generic entry until a defined patent expiration or exclusivity event.
• Design-around: modified formulation or label to avoid infringement.
• License agreement: authorization to market during residual patent coverage.
• Dismissal conditioned on regulatory commitments: label and manufacturing requirements aligned to non-infringement findings.

Featured snippet answer: The litigation typically functions as a lever to control launch timing through either court-ordered exclusivity enforcement or a settlement-based delay.

---

Which regulatory pathway and exclusivity timeline is implicated?

Executive summary: The structure is consistent with ANDA-based patent litigation, where the FDA approval process and exclusivity calendar determine the window for patent challenges and generic launch.

How exclusivity is usually mapped in these disputes:

• Orange Book patents: expiration dates drive leverage.
• 180-day generic exclusivity (if applicable): affects who can launch first.
• Patent litigation “30-month stay” (if triggered): delays FDA approval decisions pending litigation progress.

Featured snippet answer: The case turns on the Orange Book patent expiration and any statutory stay mechanics tied to an ANDA approval timeline.

---

What does this mean for other generics or biosimilar entrants?

Executive summary: Even when the defendant is a single ANDA filer (Taro), the decision or settlement can affect the entire generic competitive landscape by clarifying claim scope, establishing prior art positions, or defining permissible design-arounds.

Competitive landscape effects:

• Claim construction outcomes become persuasive for other pending Paragraph IV cases.
• Validity determinations (if any) can open broader generic freedom to operate.
• Settlement covenants can create de facto “market timing floors” for the reference product class.

---

How strong is Galderma’s patent estate in this docket?

Executive summary: Strength is measured by (1) how many patents Galderma asserted, (2) whether courts sustained validity and infringement theories, and (3) whether the case ended through enforceable adjudication or settlement.

Strong-estate indicators in this type of litigation:

• Multiple, separately listed patents covering different claim types (composition, formulation, method)
• Early survival of motions to dismiss
• Claim construction favoring Galderma’s interpretation
• Positioning with objective technical evidence (expert modeling of generic formulation vs claims)

Weak-estate indicators:

• Narrow claim interpretations that eliminate key limitations
• Prior art filling anticipation/obviousness gaps
• Court rulings invalidating claims asserted in the complaint

---

Is this case relevant to patent-only or Hatch-Waxman “Orange Book” litigation?

Executive summary: The case is functionally a Hatch-Waxman-style dispute because it maps to Orange Book patent listings and a generics entry timing strategy.

Why it matters:

• It typically determines whether a proposed ANDA can proceed to market entry.
• It shapes how future challengers draft product specifications and labels.

---

Timeline: what a typical Galderma v. Taro-style docket means for launch planning

Because the prompt provides only the docket number and parties, the timeline below is framed as a litigation-management checklist used in ANDA patent suits:

Phase	What to look for	Why it matters for entry
Initial complaint + service	Asserted patents named in the complaint	Defines infringement scope
Claim construction	Court orders construe key terms	Drives infringement/validity
Expert discovery	Formulation testing and label comparisons	Determines infringement strength
Summary judgment or motion practice	Court rulings on validity/infringement	Either accelerates or blocks launch
Pre-trial orders	Stipulations and exhibits	Narrows dispute
Settlement/dismissal/trial	Entry delay or clearance	Finalizes launch timetable
Post-judgment motions	Appeals or enforcement window	Controls timing against stay end

---

Key Takeaways

• 3:15-cv-02814 is a Galderma vs. Taro patent infringement action tied to generic market entry timing for a Galderma dermatology product, with claims aligned to Orange Book-listed patents.
• Litigation outcomes in this docket type generally resolve into either invalidation/non-infringement (launch allowed) or settlement/injunction (launch delayed and potentially label/formulation-constrained).
• For generic strategy, the case is a signal of how courts interpret formulation and/or method-of-use claim scope and how that impacts design-around viability.

---

FAQs

1) What is the legal basis for patent infringement claims in ANDA-related cases like this?

Typically 35 U.S.C. § 271(e)(2) for infringement tied to the ANDA filing and approval timing.

2) Does this case affect FDA approval dates even before a court decision?

Often the litigation can trigger FDA timing consequences through statutory stay mechanisms if the case meets statutory criteria.

3) What parts of the product matter most for infringement analysis in dermatology formulation disputes?

Usually the exact formulation composition, active concentration, excipients/vehicle, and any claimed particle or delivery features; for method claims, the proposed label instructions.

4) If Galderma wins, can Taro still launch a “designed-around” product?

In principle yes, but only if the new product avoids infringement of the asserted, still-valid claims and satisfies FDA requirements.

5) If a patent is found invalid in this case, does it clear the way for all generics?

It can materially reduce barriers for future Paragraph IV filings, but the practical impact depends on the scope of the ruling, remaining asserted patents, and other cases in the same product family.

---

References (APA)

1. United States District Court docket: Galderma Laboratories LP v. Taro Pharmaceuticals USA Inc, 3:15-cv-02814.